| Identification | Back Directory | [Name]
3-Quinolinecarboxylic acid, 6-[[(2S)-2-[([1,1'-biphenyl]-4-ylcarbonyl)amino]-1-oxopropyl]amino]-1,4-dihydro-4-oxo- | [CAS]
2580935-57-3 | [Synonyms]
PTPN22-IN-1
(S)-6-(2-([1,1'-biphenyl]-4-ylcarboxamido)propanamido)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
3-Quinolinecarboxylic acid, 6-[[(2S)-2-[([1,1'-biphenyl]-4-ylcarbonyl)amino]-1-oxopropyl]amino]-1,4-dihydro-4-oxo- | [Molecular Formula]
C26H21N3O5 | [MOL File]
2580935-57-3.mol | [Molecular Weight]
455.46 |
| Chemical Properties | Back Directory | [Boiling point ]
767.5±60.0 °C(Predicted) | [density ]
1.370±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
6.46±0.10(Predicted) | [color ]
White to yellow |
| Hazard Information | Back Directory | [Biological Activity]
PTPN22-IN-1 is a potent PTPN22 inhibitor (IC50=1.4 μM; Ki=0.50 μM). PTPN22-IN-1 exhibits >7-10 fold selectivity for PTPN22 over similar phosphatases. PTPN22-IN-1 augments antitumor immune responses[1]. From WO2021007491A1 compound L-1.
PTPN22-IN-1 (Compound L-1) (WT mice; intraperitoneally) significantly reduces MC38 tumor growth. PTPN22-IN-1 (syngeneic immunocompetent model; CT26 in Balb/c mice) shows similar antitumor effects[1].Administration of L-l intraperitoneally at 10 mg/kg yielded an average AUC of 4.55 μM h and Cmax of 1.1 1 μM (Fig. 9d), which is more than twice of its Ki value[1].
PTPN22-IN-1 (Compound L-1) (WT mice; intraperitoneally) significantly reduces MC38 tumor growth. PTPN22-IN-1 (syngeneic immunocompetent model; CT26 in Balb/c mice) shows similar antitumor effects[1].Administration of L-l intraperitoneally at 10 mg/kg yielded an average AUC of 4.55 μM h and Cmax of 1.1 1 μM (Fig. 9d), which is more than twice of its Ki value[1]. | [References]
[1]. Elizabeth Jaffee, et al. Targeting ptpn22 in cancer therapy. WO2021007491A1. |
|
|